作　　者： ;

机构地区： 广东药科大学

出　　处： 《工业工程》 2017年第5期38-44,共7页

摘　　要： 为了解我国医药制造业技术创新系统的协同演化状态和规律，基于技术创新价值链和复杂系统论视角，将该系统解构为技术内部研发、技术外部获取、商业化、技术创新支撑环境等4个子系统，采用2007～2015年度统计年鉴数据，运用复合系统协同度模型对该系统演化的协同度及其各子系统的有序度进行测度和分析。结果表明，该系统的协同度及其各子系统的有序度随时间推移呈动态上升趋势，但其平均值较低；技术外部获取子系统是制约该系统向高水平协同发展的“短板”；不同序参量对其所属子系统有序度的影响权重不一；我国医药行业重大政策可能对系统协同发展产生明显的短期效应。最后，提出有针对性的政策建议。 Based on the perspectives of technology innovation value chain and complex systems theory, the Chinese pharmaceutical industry technology innovation system can be deconstructed into four subsystems of internal technology R＆D, external technology acquisition, commercialization and innovation supporting environment, to understand the evolution state and rule of this system. Using the data of statistical yearbook from 2007-2015 and the synergy degree model of composite system, this system＇s synergy degree and its subsystems＇ ordering degree in the evolution process are measured and analyzed. The results show that this system＇s overall synergy degree and its subsystems＇ ordering degree show a dynamically rising trend as time goes on but their average values are low; technology external acquisition subsystem is the restriction factor for the synergy development of the whole system to the high level; the influencing weights of different order parameters on their respective subsystems＇ ordering degree are different; the significant polices for China＇s pharmaceutical industry may produce a clear short-term effect on the system＇s synergy development. Finally, some policy recommendations are made based on the above conclusions.

关 键 词： 医药制造业 技术创新系统 协同度

分 类 号： [F062.4]

领　　域： []